On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled for the international Frontiers in Biomagnetic Particles conference in Asheville, North Carolina. Carried out by researchers from Imagion Biosystems, the University of New Mexico, and Sandia National Laboratories, the study demonstrated the use of superparamagnetic relaxometry (SPMR) for specific detection of HER2 positive tumors in mice. The results suggest the utility of SPMR for sensitive and specific detection of cancer, and represent another successful step in the progression of Imagion Biosystems technology. Download the abstract of Dr. Vreeland’s presentation.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority